Research library / Resveratrol and sirtuins

CC Small or few human trials. Promising, not proven. How we grade →Phase 2 trial (single arm) · 24 patients with relapsed or refractory multiple myeloma

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

R Popat, T Plesner, F Davies, G Cook, M Cook, P Elliott et al. British Journal of Haematology. 2013.

Published Sources checked 1 sourceEverstack research teamHow we work

In plain language
SRT501, a 5 g a day resveratrol formulation, given with bortezomib was stopped after 24 patients; the ClinicalTrials.gov record (NCT00920556) lists serious acute renal failure in 3 and renal failure in 2.
Limits
Sponsored by Sirtris, a GSK company. Myeloma itself harms the kidneys and there was no control group, so cause is uncertain. A drug dose far above supplements.
Which of our grades it feeds
Source
doi.org/10.1111/bjh.12154 · PubMed 23205612

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.